Get the Stockscreener App
51.22
0.49%
-0.25
After Hours:
51.15
-0.07
-0.14%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $51.22, with a volume of 10.36M.
It is down -0.49% in the last 24 hours and up +3.79% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$51.47
Open:
$51.52
24h Volume:
10.36M
Relative Volume:
0.62
Market Cap:
$227.60B
Revenue:
$46.69B
Net Income/Loss:
$15.29B
P/E Ratio:
14.92
EPS:
3.4329
Net Cash Flow:
$9.25B
1W Performance:
-0.76%
1M Performance:
+3.79%
6M Performance:
-25.24%
1Y Performance:
-40.25%
1-Day Range:
$51.06
$51.67
1-Week Range:
$51.06
$53.63
52-Week Range:
$43.08
$93.80
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
51.22 | 228.71B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
1,079.75 | 965.48B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.91 | 500.07B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.74 | 407.98B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
138.72 | 267.10B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
106.06 | 264.63B | 63.90B | 19.05B | 13.05B | 7.5596 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-25 | Downgrade | Argus | Buy → Hold |
| Oct-27-25 | Resumed | Jefferies | Underperform |
| Oct-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-29-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Sep-16-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study - GlobeNewswire Inc.
The Truth About Novo Nordisk A/S (ADR): Is Wall Street’s Favorite ‘Skinny Stock’ Still Worth t - AD HOC NEWS
Where is Novo Nordisk A/S (NVO) Headed? - Finviz
Novo Nordisk (NVO) Gets 9% Boost from Wegovy Pill OK - Finviz
Should You Invest in Ozempic Maker Novo Nordisk in 2026? - Finviz
What Does the Market Think About Novo Nordisk AS? - Sahm
The New York Stock Exchange | NYSE - NYSE
Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus
Why Novo Nordisk Stock Popped Today - Finviz
Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus - Sahm
Novo Nordisk stock split: what’s next for NVO shares? - Capital.com
Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback - Sahm
Novo Nordisk Share Price Jumps After FDA Clears Wegovy Pill | Stock Market Today - Samco
Novo Nordisk surges after US approves weight loss pill - Sharecast.com
Novo Nordisk Shares Surge 7% In Tuesday Pre-Market After US FDA Approves Wegovy Pill - Sahm
Novo Nordisk stock jumps over 7% after weight loss drug Wegovy pill gets US FDA nod — Details here - livemint.com
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead? - Finviz
Will Novo Nordisk A s (b Shares) Adrhedged stock benefit from infrastructure spendingJuly 2025 News Drivers & Expert Approved Trade Ideas - Улправда
How Novo Nordisk A s (b Shares) Adrhedged stock valuations compare to rivalsJuly 2025 Analyst Calls & Safe Entry Trade Signal Reports - Улправда
Tech Rally: Will Novo Nordisk A s (b Shares) Adrhedged stock maintain momentum in 2025July 2025 Volume & Low Risk High Reward Ideas - Улправда
Why Novo Nordisk A s (b Shares) Adrhedged stock remains resilientWeekly Stock Analysis & Risk Controlled Stock Alerts - Улправда
Will Novo Nordisk A s (b Shares) Adrhedged stock outperform value stocksJuly 2025 Momentum & High Yield Equity Trading Tips - Улправда
Novo Nordisk (NVO) Receives Positive Opinion For Wegovy By European Medicines Agency - Finviz
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema - Finviz
Targets Report: Will Novo Nordisk A s (b Shares) Adrhedged stock benefit from infrastructure spendingEarnings Performance Report & AI Forecasted Stock Moves - Улправда
Will Novo Nordisk A s (b Shares) Adrhedged stock maintain momentum in 2025Gap Down & Long-Term Safe Investment Ideas - Улправда
Resistance Check: How Novo Nordisk A s (b Shares) Adrhedged stock valuations compare to rivals2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
Novo Nordisk (NVO) Fell Following a Profit Warning Release - Finviz
Better Buy in 2026: Novo Nordisk or Intuitive Surgical? - Finviz
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk - Finviz
UBS Reiterates Neutral on Novo Nordisk A/S (NVO) Despite Wegovy Dose Progress - Finviz
Novo Nordisk (NVO) Hit By Lowered Guidance - Finviz
Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars - Sahm
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval - Finviz
2 Predictions for Novo Nordisk in 2026 - Finviz
Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead - ts2.tech
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch - Sahm
Novo Nordisk (NVO) experiences muted sentiment from analysts - MSN
Novo Nordisk (NVO) Experiences Muted Sentiment From Analysts - Finviz
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):